WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical…
WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…
Simon Bailey, Ph.D., Chief Operating Officer and President of R&D, Unnatural Products SANTA CRUZ, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE)…
TAMPA, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) announced that Eric Reimer, CEO of…
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company…
Nes-Ziona, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…
ROCKAWAY, N.J., Nov. 20, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is…
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase…
SAN MATEO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated…
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials…